From obesity and diabetes to heart and liver disease, the applications for GLP-1 drugs have multiplied since Ozempic arrived on the scene seven years ago. Now, Novo is testing their effect on Alzheimer’s.
www.bloomberg.com
#Novo #High #Hopes #Ozempic #Pill #Fight #Dementia
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.…
Former President Rumen Radev, who opposes sanctions against Russia and military aid for Ukraine, is on track to win Bulgaria’s…
Bloomberg News Senior Investigative Reporter Jason Leopold and author of the FOIA Files newsletter joins Bloomberg Businessweek Daily to discuss…
